4528:TYO
Ono Pharmaceutical Co Ltd
2Â 257,50Â JPY
arrow_downward
−0,73%(−16,50) 1 d
7 okt., 15:30:00 GMT+9 · JPY
search
Alla symboler
| Symbol | Pris | Ändring | Ändring i procent |
|---|
insights_autoGenererar de viktigaste insikterna för 4528 …
Öppen
2Â 262Â JPY
Högt
2Â 286Â JPY
LÃ¥gt
2Â 258Â JPY
Börsvärde
1,13Â bn
Genomsn. vol.
1,44Â mn
Volym
1,96Â mn
Utdelning
3,54Â %
Kvartalsvis utdelning
20Â JPY
Ex-utdelningsdatum
29 sep. 2026
P/E-tal
13,92
52v högst
2Â 674Â JPY
52v lägst
1Â 703Â JPY
EPS
162Â JPY
Utestående aktier
514,12Â mn
Antal anställda
4Â tn
Öppen
2Â 262Â JPY
Högt
2Â 286Â JPY
LÃ¥gt
2Â 258Â JPY
Börsvärde
1,13Â bn
Genomsn. vol.
1,44Â mn
Volym
1,96Â mn
Utdelning
3,54Â %
Kvartalsvis utdelning
20Â JPY
Ex-utdelningsdatum
29 sep. 2026
P/E-tal
13,92
52v högst
2Â 674Â JPY
52v lägst
1Â 703Â JPY
EPS
162Â JPY
Utestående aktier
514,12Â mn
Antal anställda
4Â tn
Nyheter och artiklar
Från webbkällor och nyhetspartner
Vietnam.vn
·
för 21 timmar sedan
Snabbläsning 7-10: S&P 500 når ny topp på 7 800 poäng, GVR och Vinatex presenterar 9-månadersresultat.
Dagens Industri
·
för 1 dag sedan
Uppåt på Wall Street – nytt rekord för S&P 500
Yahoo Finance
·
för 1 timme sedan
We Are Witnessing the Stock Market Do Something for Only the 3rd Time in 156 Years, and History Is Clear About What Comes Next
24/7 Wall St.
·
för 31 minuter sedan
JEPQ Trailed the Nasdaq-100 by $17,970 on $300,000 Over One Year. The Covered Calls Are Why
Profil
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
Om Ono Pharmaceutical Co Ltd
VdGyo Sagara | Gyo Sagara
Anställda4,21 tn
Grundades1717
HuvudkontorOsaka, Osaka prefektur, Japan
Sektor-
Webbplatsono-pharma.com